Status:
NOT_YET_RECRUITING
Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Colorectal Cancer (Diagnosis)
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to learn if combining serplulimab (PD-1 inhibitor) with bevacizumab and short-course total neoadjuvant therapy (TNT) works to treat locally advanced mid-to-low recta...
Eligibility Criteria
Inclusion
- Participants must meet all of the following criteria to be eligible for the study:
- Age: 18 to 75 years old.
- Diagnosis: Pathologically confirmed rectal adenocarcinoma with proficient mismatch repair (pMMR) / microsatellite stable (MSS) status, based on biopsy of the primary tumor.
- Disease Stage: Untreated, preoperative clinical stage cT2-T4 and/or N+, M0 (AJCC 8th edition), unsuitable for initial local excision to achieve radical cure.
- Tumor Location: Tumor within 8 cm from the anal verge, or assessed by surgeons as not suitable for immediate sphincter-preserving surgery.
- Organ Preservation Intent: Strong desire for sphincter preservation and willingness to accept close surveillance for at least 2 years after chemoradiotherapy.
- Surgical Candidacy: Agrees to undergo radical surgery and judged by surgeon to have no contraindication to surgery.
- Cancer History: No concurrent multiple primary malignancies.
- Measurable Lesions: At least one measurable or evaluable lesion according to RECIST v1.1 criteria.
- Life Expectancy: ≥ 3 months.
- Performance Status: ECOG performance status score of 0-1.
- Compliance: Good compliance and willingness to sign written informed consent.
Exclusion
- Participants will be excluded if any of the following conditions apply:
- Molecular Subtype: Rectal cancer with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status.
- Autoimmune Disease: Active, known, or suspected autoimmune disease.
- Immunodeficiency: Known history of primary immunodeficiency.
- Transplant History: History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Pregnancy or Lactation: Pregnant or breastfeeding women.
- Urgent Surgical Indications: Intestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency surgery.
- Uncontrolled Comorbidities, including but not limited to:
- HIV infection (HIV antibody positive) Active or poorly controlled severe infection Active hepatitis Severe or uncontrolled systemic diseases (e.g., severe psychiatric or neurological disorders, epilepsy, dementia, unstable or decompensated respiratory, cardiovascular, hepatic, or renal disease, uncontrolled hypertension ≥ CTCAE Grade 2 despite medication) Active bleeding or recent thrombotic disease requiring therapeutic anticoagulation, or bleeding tendency, or coagulation abnormalities (INR \> 1.5 × ULN, APTT \> 1.5 × ULN)
- Laboratory Abnormalities at Baseline:
- Hemoglobin \< 80 g/L Absolute neutrophil count (ANC) \< 1.5 × 10⁹/L Platelets \< 80 × 10⁹/L ALT or AST \> 2.5 × ULN ALP \> 2.5 × ULN Total bilirubin ≥ 1.5 × ULN Serum creatinine ≥ 1 × ULN
- Allergy: Known hypersensitivity to any component of the investigational drugs.
- Other Clinical Trial Participation: Currently enrolled in another interventional drug clinical trial.
- Other Conditions: Any other condition judged by the investigator to make the patient unsuitable for the study.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2030
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT07134101
Start Date
September 1 2025
End Date
August 31 2030
Last Update
August 29 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.